Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.

被引：0
|
作者：
Pant, Shubham
Schuler, Martin H.
Iyer, Gopa
Witt, Olaf
Doi, Toshihiko
Qin, Shukui
Tabernero, Josep
Reardon, David A.
Massard, Christophe
Welsh, Liam
Lugowska, Iwona A.
Carranza, Omar
Stuyckens, Kim
Liao, Huimin
Najmi, Saltanat
Hammond, Constance
Thomas, Shibu
Triantos, Spyros
Sweiti, Hussein
Loriot, Yohann
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Heidelberg Hosp, Hopp Childrens Canc Ctr KiTZ, German Canc Res Ctr Heidelberg, Heidelberg, Germany
[5] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany
[6] Natl Canc Ctr Hosp East, Chiba, Japan
[7] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[10] Dana Farber Canc Inst, Boston, MA USA
[11] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[12] Royal Marsden NHS Fdn Trust, London, England
[13] Narodowy Instytut Onkologii, Marii Sklodowskiej Curie Panstwowy Inst Badawczy, Warsaw, Poland
[14] Hosp Privado Comunidad Mar Plata, Mar Del Plata, Argentina
[15] Janssen Res & Dev, Beerse, PA, Belgium
[16] Janssen Res & Dev, Shanghai, Peoples R China
[17] Janssen Res & Dev, Spring House, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3121
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors
    Valade, Elodie
    Dosne, Anne-Gaelle
    Xie, Hong
    Kleiman, Robert
    Li, Lilian Y.
    Perez-Ruixo, Juan Jose
    Ouellet, Daniele
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 621 - 633
  • [32] Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
    Schuler, M.
    Tabernero, J.
    Massard, C.
    Iyer, G. Vasudeva
    Witt, O.
    Doi, T.
    Qin, S.
    Lu-Emerson, C.
    Hargrave, D.
    Garcia-Corbacho, J.
    Little, S.
    Xia, Q.
    Santiago-Walker, A.
    Moy, C. H.
    Hammond, C.
    Lau, Y. Y.
    Sweiti, H.
    Pant, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S502 - S503
  • [33] Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database
    Jiang, Cindy Y.
    Hwang, Hyunsoo
    Jindal, Tanya
    Qiao, Wei
    Epstein, Ilana
    Nguyen, Charles B.
    Gupta, Shilpa
    Shah, Sumit
    Bilen, Mehmet Asim
    Milowsky, Matthew I.
    Hoimes, Christopher J.
    Kilari, Deepak
    Zakharia, Yousef
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    Campbell, Matthew T.
    Alhalabi, Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [34] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediaterisk non-muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.
    Daneshmand, Siamak
    Zaucha, Renata
    Gartrell, Benjamin Adam
    Lotan, Yair
    Hussain, Syed A.
    Lee, Eugene K.
    Procopio, Giuseppe
    Galanternik, Fernando
    Naini, Vahid
    Carcione, Jenna
    Triantos, Spyros
    Baig, Mahadi
    Maranchie, Jodi K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations
    Feng, Yin-Hsun
    Su, Wu-Chou
    Oh, Do-Youn
    Shen, Lin
    Kim, Kyu-Pyo
    Liu, Xiufeng
    Liao, Huimin
    Qing, Min
    Qian, Jiaqi
    Triantos, Spyros
    Sweiti, Hussein
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [36] Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.
    Jogo, Tomoko
    Shinozaki, Eiji
    Masuishi, Toshiki
    Kato, Takeshi
    Nishina, Tomohiro
    Esaki, Taito
    Komatsu, Yoshito
    Kato, Ken
    Suzuki, Mitsuko
    Fuse, Nozomu
    Sato, Akihiro
    Ikeno, Takashi
    Nomura, Shogo
    Bando, Hideaki
    Odegaard, Justin Iver
    Fujii, Satoshi
    Ebi, Hiromichi
    Yoshino, Takayuki
    Nakamura, Yoshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
    Santin, Alessandro D.
    Corr, Bradley R.
    Spira, Alexander
    Willmott, Lyndsay
    Butrynski, James
    Tse, Ka Yu
    Patel, Jilpa
    Mekan, Sabeen
    Wu, Tia
    Lin, Kai-Wen
    Kuo, Peiwen
    Dumbrava, Ecaterina E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
  • [38] Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
    Krzakowski, Maciej Jerzy
    Lu, Shun
    Cousin, Sophie
    Smit, Egbert F.
    Springfeld, Christoph
    Goto, Koichi
    Garrido, Pilar
    Chung, Christine H.
    Lin, Jessica Jiyeong
    Bray, Victoria J.
    Pitcher, Bethany
    Zeuner, Harald
    Patel, Siddhartha
    Bordogna, Walter
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
    Cheng, Ying
    Liu, Ying
    Xu, Jinhua
    Zhu, Jing
    Wang, Ying
    Xin, Ying
    Wang, Yanping
    Wu, Chunjiao
    Cui, Hongxia
    Liu, Xianhong
    Dai, Jixin
    Li, Zili
    Zhang, XiangHua
    Zhang, Jing
    Zhang, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study
    Andre, Thierry
    Berton, Dominique
    Curigliano, Giuseppe
    Jimenez-Rodriguez, Begona
    Ellard, Susan
    Gravina, Adriano
    Miller, Rowan
    Tinker, Anna
    Jewell, Andrea
    Pikiel, Joanna
    Oaknin, Ana
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Banerjee, Susana N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345